Market Research Logo

Pain Drug Development Pipeline Review, 2018

Pain Drug Development Pipeline Review, 2018

Summary

Pain is one of the main post-operative adverse outcomes causing distress to patients. Causes of post-operative pain include peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics. There are 74 products in development for this indication.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs. There are 21 products in development for this indication.

CRPS is a chronic pain condition that most often affects one limb, usually after an injury. CRPS is divided into two types: CRPS-I (individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in the affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams. There are seven products in development for this indication.

Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or nonsteroidal anti-inflammatory drugs and pain modifiers such as tricyclic antidepressants or anticonvulsants. There are 38 products in development for this indication.

Molecular targets acted on by products in development for pain disorders include beta nerve growth factor, cannabinoid receptors, opioid receptors and protein kinases. Companies operating in this pipeline space include NeurAxon, Abide Therapeutics and Pfizer.

This report “Pain Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for pain disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-operative pain, fibromyalgia, complex regional pain syndrome (CRPS) and visceral pain, and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Pain Report Coverage
2.2 Post-Operative Pain - Overview
2.3 Fibromyalgia - Overview
2.4 Complex Regional Pain Syndrome - Overview
2.5 Visceral Pain - Overview
3 Therapeutics Development
3.1 Post-Operative Pain
3.2 Fibromyalgia
3.3 Complex Regional Pain Syndrome
3.4 Visceral Pain
4 Therapeutics Assessment
4.1 Post-Operative Pain
4.2 Fibromyalgia
4.3 Complex Regional Pain Syndrome
4.4 Visceral Pain
5 Companies Involved in Therapeutics Development
5.1 Post-Operative Pain
5.2 Fibromyalgia
5.3 Complex Regional Pain Syndrome
5.4 Visceral Pain
6 Dormant Projects
6.1 Post-Operative Pain
6.2 Fibromyalgia
6.3 Complex Regional Pain Syndrome
6.4 Visceral Pain
7 Discontinued Products
7.1 Post-Operative Pain
7.2 Fibromyalgia
7.3 Visceral Pain
8 Product Development Milestones
8.1 Post-Operative Pain
8.2 Fibromyalgia
8.3 Complex Regional Pain Syndrome
8.4 Visceral Pain
9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Number of Products under Development for Post-Operative Pain
Table 2: Number of Products under Development by Companies, Post-Operative Pain
Table 3: Number of Products under Development by Universities/Institutes, Post-Operative Pain
Table 4: Products under Development by Companies, Post-Operative Pain
Table 5: Products under Development by Universities/Institutes, Post-Operative Pain
Table 6: Number of Products under Development for Fibromyalgia
Table 7: Number of Products under Development by Companies, Fibromyalgia
Table 8: Number of Products under Development by Universities/Institutes, Fibromyalgia
Table 9: Products under Development by Companies, Fibromyalgia
Table 10: Products under Development by Universities/Institutes, Fibromyalgia
Table 11: Number of Products under Development for Complex Regional Pain Syndrome
Table 12: Number of Products under Development by Companies, Complex Regional Pain Syndrome
Table 13: Number of Products under Development by Universities/Institutes, Complex Regional Pain Syndrome
Table 14: Products under Development by Companies, Complex Regional Pain Syndrome
Table 15: Products under Development by Universities/Institutes, Complex Regional Pain Syndrome
Table 16: Number of Products under Development for Visceral Pain
Table 17: Number of Products under Development by Companies, Visceral Pain
Table 18: Number of Products under Development by Universities/Institutes, Visceral Pain
Table 19: Products under Development by Companies, Visceral Pain
Table 20: Products under Development by Universities/Institutes, Visceral Pain
Table 21: Number of Products by Stage and Target, Post-Operative Pain
Table 22: Number of Products by Stage and Mechanism of Action, Post-Operative Pain
Table 23: Number of Products by Stage and Route of Administration, Post-Operative Pain
Table 24: Number of Products by Stage and Molecule Type, Post-Operative Pain
Table 25: Number of Products by Stage and Target, Fibromyalgia
Table 26: Number of Products by Stage and Mechanism of Action, Fibromyalgia
Table 27: Number of Products by Stage and Route of Administration, Fibromyalgia
Table 28: Number of Products by Stage and Molecule Type, Fibromyalgia
Table 29: Number of Products by Stage and Target, Complex Regional Pain Syndrome
Table 30: Number of Products by Stage and Mechanism of Action, Complex Regional Pain Syndrome
Table 31: Number of Products by Stage and Route of Administration, Complex Regional Pain Syndrome
Table 32: Number of Products by Stage and Molecule Type, Complex Regional Pain Syndrome
Table 33: Number of Products by Stage and Target, Visceral Pain
Table 34: Number of Products by Stage and Mechanism of Action, Visceral Pain
Table 35: Number of Products by Stage and Route of Administration, Visceral Pain
Table 36: Number of Products by Stage and Molecule Type, Visceral Pain
Table 37: Post-Operative Pain - Pipeline by Abide Therapeutics Inc
Table 38: Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc
Table 39: Post-Operative Pain - Pipeline by Adynxx Inc
Table 40: Post-Operative Pain - Pipeline by AngioChem Inc
Table 41: Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc
Table 42: Post-Operative Pain - Pipeline by Apsen Farmaceutica SA
Table 43: Post-Operative Pain - Pipeline by Cadila Healthcare Ltd
Table 44: Post-Operative Pain - Pipeline by Camurus AB
Table 45: Post-Operative Pain - Pipeline by Cara Therapeutics Inc
Table 46: Post-Operative Pain - Pipeline by Center Laboratories Inc
Table 47: Post-Operative Pain - Pipeline by CerSci Therapeutics Inc
Table 48: Post-Operative Pain - Pipeline by Colby Pharmaceutical Co
Table 49: Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA
Table 50: Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc
Table 51: Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc
Table 52: Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp
Table 53: Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc
Table 54: Post-Operative Pain - Pipeline by Heron Therapeutics Inc
Table 55: Post-Operative Pain - Pipeline by Immupharma Plc
Table 56: Post-Operative Pain - Pipeline by Innocoll AG
Table 57: Post-Operative Pain - Pipeline by Insys Therapeutics Inc
Table 58: Post-Operative Pain - Pipeline by Ionis Pharmaceuticals Inc
Table 59: Post-Operative Pain - Pipeline by iX Biopharma Ltd
Table 60: Post-Operative Pain - Pipeline by Jiangsu Hengrui Medicine Co Ltd
Table 61: Post-Operative Pain - Pipeline by Lipocure Ltd
Table 62: Post-Operative Pain - Pipeline by Liquidia Technologies Inc
Table 63: Post-Operative Pain - Pipeline by Lumosa Therapeutics Co Ltd
Table 64: Post-Operative Pain - Pipeline by Medtronic Plc
1.2 List of Figures
Figure 1: Number of Products under Development for Post-Operative Pain
Figure 2: Number of Products under Development by Companies, Post-Operative Pain
Figure 3: Number of Products under Development by Universities/Institutes, Post-Operative Pain
Figure 4: Number of Products under Development for Fibromyalgia
Figure 5: Number of Products under Development by Companies, Fibromyalgia
Figure 6: Number of Products under Development for Complex Regional Pain Syndrome
Figure 7: Number of Products under Development by Companies, Complex Regional Pain Syndrome
Figure 8: Number of Products under Development for Visceral Pain
Figure 9: Number of Products under Development by Companies, Visceral Pain
Figure 10: Number of Products under Development by Universities/Institutes, Visceral Pain
Figure 11: Number of Products by Top 10 Targets, Post-Operative Pain
Figure 12: Number of Products by Stage and Top 10 Targets, Post-Operative Pain
Figure 13: Number of Products by Top 10 Mechanism of Actions, Post-Operative Pain
Figure 14: Number of Products by Stage and Top 10 Mechanism of Actions, Post-Operative Pain
Figure 15: Number of Products by Top 10 Routes of Administration, Post-Operative Pain
Figure 16: Number of Products by Stage and Top 10 Routes of Administration, Post-Operative Pain
Figure 17: Number of Products by Molecule Types, Post-Operative Pain
Figure 18: Number of Products by Stage and Molecule Types, Post-Operative Pain
Figure 19: Number of Products by Top 10 Targets, Fibromyalgia
Figure 20: Number of Products by Stage and Top 10 Targets, Fibromyalgia
Figure 21: Number of Products by Top 10 Mechanism of Actions, Fibromyalgia
Figure 22: Number of Products by Stage and Top 10 Mechanism of Actions, Fibromyalgia
Figure 23: Number of Products by Routes of Administration, Fibromyalgia
Figure 24: Number of Products by Stage and Routes of Administration, Fibromyalgia
Figure 25: Number of Products by Molecule Types, Fibromyalgia
Figure 26: Number of Products by Stage and Molecule Types, Fibromyalgia
Figure 27: Number of Products by Targets, Complex Regional Pain Syndrome
Figure 28: Number of Products by Stage and Targets, Complex Regional Pain Syndrome
Figure 29: Number of Products by Mechanism of Actions, Complex Regional Pain Syndrome
Figure 30: Number of Products by Stage and Mechanism of Actions, Complex Regional Pain Syndrome
Figure 31: Number of Products by Routes of Administration, Complex Regional Pain Syndrome
Figure 32: Number of Products by Stage and Top 10 Routes of Administration, Complex Regional Pain Syndrome
Figure 33: Number of Products by Stage and Molecule Types, Complex Regional Pain Syndrome
Figure 34: Number of Products by Top 10 Targets, Visceral Pain
Figure 35: Number of Products by Stage and Top 10 Targets, Visceral Pain
Figure 36: Number of Products by Top 10 Mechanism of Actions, Visceral Pain
Figure 37: Number of Products by Stage and Top 10 Mechanism of Actions, Visceral Pain
Figure 38: Number of Products by Routes of Administration, Visceral Pain
Figure 39: Number of Products by Stage and Routes of Administration, Visceral Pain
Figure 40: Number of Products by Molecule Types, Visceral Pain
Figure 41: Number of Products by Stage and Molecule Types, Visceral Pain

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report